PDCD1 and metastatic melanoma: In humans, both primary and metastatic melanomas, but not normal skin, express MCP-152, and antagonism of its receptor CCR2 enhanced the therapeutic efficacy of anti-PD-1 antibody in a murine melanoma model53.